On February 26, 2018 Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, is hosting an analyst and investor event to present Phase 2 results from its HS-110 (viagenpumatucel-L) study in combination with the Bristol-Myers Squibb checkpoint inhibitor, nivolumab (Opdivo), in patients with advanced non-small cell lung cancer (NSCLC) whose cancers have progressed after treatment with one or more lines of therapy (Press release, Heat Biologics, FEB 26, 2018, View Source [SID1234524164]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will take place at 8 a.m., Wednesday, Feb. 28, 2018, at the Lotte New York Palace Hotel in New York City. To register and watch a live webcast of the event, visit View Source

The event follows the first formalized Independent Data Monitoring Committee ("IDMC") meeting review of the most recent Phase 2 interim data from the trial. The presentation will include data generated from the first 35 patients enrolled in the study, specifically:

Clinical efficacy measures of treatment response
The correlation of immune response from blood samples with positive clinical outcome
Safety data evaluation and analysis
Speakers include Roger B. Cohen, MD, Professor of Medicine at the University of Pennsylvania and Associate Director for Clinical Research for the Abramson Cancer Center, who will discuss the current treatment landscape for NSCLC, and the emerging role of combination immunotherapy treatments. Following Dr. Cohen’s presentation, George Peoples, MD, Chief Medical Officer for Heat, will discuss the latest Phase 2 results from the HS-110 study. Heat management will also provide an outline of the company’s planned development strategy for HS-110 based on the trial data, as well as the recent outcome of its Type C meeting with the FDA.

On February 26, 2018 OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, reported an update on the status of the two planned clinical trials of ProscaVax for prostate cancer (Press release, Oncbiomune, FEB 26, 2018, View Source [SID1234524354]). ProscaVax is OncBioMune’s lead immunotherapy candidate consisting of a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). The Company has successfully completed a Phase 1a clinical trial of ProscaVax in hormone-naïve and hormone-independent recurrent prostate cancer patients with increasing PSA and the patients continue to be followed for additional endpoints.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OncBioMune is moving forward with two separate clinical trials evaluating ProscaVax. One clinical trial is in advanced cancer patients in conjunction with the Urology Clinics of North Texas ("UCNT") and the second is front-line therapy in early-stage cancer patients, which is to be hosted at a teaching hospital of Harvard University Medical School in Boston, MA.

With respect to the Phase 2 clinical trial hosted by UCNT, the company is preparing the protocol for FDA submission. For FDA approval the company will use a central IRB (Institutional Review Board), as central IRBs move much faster than most university IRBs.

As for the Phase 2 clinical trial at the Harvard University teaching hospital, the Protocol has been approved by the Nursing Committee, Pharmacists, the Regulatory Committee and is under review by the Scientific Review Committee. After approval patient enrollment will begin.

Company Chief Financial Officer Andrew Kucharchuk added, "We are excited to be building such great momentum in 2018. Having a clinical trial in both early and late stage prostate cancer that will be enrolling patients in the coming months, combined with the progress we are making on our other platform therapies, particularly OvcaVaxTM, shows we are moving full speed ahead in 2018.

On February 26, 2018 Horizon Pharma plc (NASDAQ:HZNP) reported that the company will present at the following conference in March (Press release, Horizon Pharma, FEB 26, 2018, View Source [SID1234524165]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen and Company 38th Annual Health Care Conference

Date: March 12, 2018
Presentation Time: 4:10 p.m. ET
Location: Boston, Mass.
The presentation will be webcast live and may be accessed by visiting Horizon’s website at View Source A replay of the webcast will be available for the event.

On February 28, 2018 Bristol-Myers Squibb Company (NYSE:BMY) reported that Yale Cancer Center has joined the International Immuno-Oncology Network (II-ON), a global peer-to-peer collaboration between Bristol-Myers Squibb and academia that aims to advance translational Immuno-Oncology (I-O) science (Press release, Bristol-Myers Squibb, FEB 26, 2018, View Source [SID1234524637]). Formed in 2012 by Bristol-Myers Squibb, the II-ON was one of the first networks to bring academia and industry together to further the scientific understanding of I-O, and has since expanded from 10 to 16 sites across North America, Europe, Japan and Australia.Today, the partners collaborate to generate innovative I-O science, launch biology-driven trials and apply cutting-edge technologies with the goal of translating research findings into clinical trials and, ultimately, supporting efforts to improve survival outcomes across tumor types.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The II-ON gives us the chance to work more efficiently and collaboratively with Bristol-Myers Squibb and the other II-ON academic centers to address scientific questions in I-O," said Roy Herbst, M.D., Ph.D., director of the Center of Immuno-Oncology at Yale Cancer Center and Yale’s principal investigator of the II-ON team. "The hope is this early research can someday inform clinical trials and ultimately help us to achieve our goal of transforming the way we treat people affected by cancer."

The II-ON was formed on the foundation of three fundamental scientific pillars aimed at addressing key research priorities in I-O: understanding the mechanisms of resistance to immunotherapy; identifying patient populations likely to benefit from immunotherapy; and exploring novel combination therapies that may enhance anti-tumor response through complementary mechanisms of action. By providing a streamlined framework for peer-to-peer collaboration among global cancer research leaders, the network is able to more rapidly facilitate I-O innovation and drug discovery.

"Translational medicine and the understanding of cancer biology are foundational to our oncology R&D program, which is why we’re invested in furthering our understanding of early I-O science through the II-ON," said Nils Lonberg, head of Oncology Biology Discovery at Bristol-Myers Squibb. "By adding Yale Cancer Center to the network, we are strengthening our collective ability to address essential scientific questions and advance clinical discovery, which we hope will eventually translate to meaningful outcomes for patients."

Bristol-Myers Squibb believes the future of cancer research is dependent on investments in science and partnerships. In addition to the II-ON, the company has invested in several other models of scientific collaboration with academic partners across the globe, including the Global Expert Centers Initiative (GECI), the Immuno-Oncology Integrated Community Oncology Network (IO-ICON) and the Oncology Academic Research (OAR) Group.

On February 26, 2018 Omeros Corporation (NASDAQ: OMER) reported that the company will issue its fourth quarter and year-end 2017 financial results for the period ended December 31, 2017, on Thursday, March 1, 2018, after the market closes (Press release, Omeros, FEB 26, 2018, View Source;p=RssLanding&cat=news&id=2334619 [SID1234524166]). Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Details

To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally. The participant passcode is 1759244. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 1759244.

To access the live and subsequently archived webcast of the conference call, go to Omeros’ website at www.omeros.com and go to "Events" under the Investors section of the website. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.